ERBB2 and cancer: ER/PR/HER2 was strongly associated with OS (P < 0.01), with patients with triple-negative breast cancer experiencing a 2.21-fold (95% CI: 1.28, 3.81) increase in the hazard of death compared to those with HER2-negative, ER- and/or PR-positive cancer.